Christoph Hess

4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom.

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.

Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation.

Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY.

RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI.

UltraSoC Technologies Ltd. engages in the development of debugging technology for the embedded electronic systems. It offers semiconductor IP for on-chip analytics, performance optimization, and hardware-based security. The company was founded by Stephen Karl Heeks, Andrew Brian Thomas Hopkins, and Klaus Dieter McDonald-Maier in 2006 and is headquartered in Cambridge, the United Kingdom.

Detego Ltd. develops and distributes innovative software products for the fashion retail industry. Its products include Detego Suite, Detego InWarehousem Detego InStore, Detego InChannels, and Detego InReports. The company was founded in 2011 and is headquartered in London, the United Kingdom.

Enso Ventures Ltd (Enso Ventures) is an independent venture capital firm founded in 2010 by Nikolay Danilov. The firm is headquartered in London, United Kingdom.